<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373879">
  <stage>Registered</stage>
  <submitdate>25/10/2017</submitdate>
  <approvaldate>31/10/2017</approvaldate>
  <actrnumber>ACTRN12617001519347</actrnumber>
  <trial_identification>
    <studytitle>Effect of atropine eye drops on thinning of the ocular choroid induced by retinal image defocus in adults with myopia (near-sightedness)</studytitle>
    <scientifictitle>Effect of atropine eye drops on choroidal thinning induced by hyperopic retinal defocus in adults with myopia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myopia</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>One drop 0.5% atropine eye drop to non-dominant eye on one occasion, instilled by the research optometrist</interventions>
    <comparator>Sequential no-treatment - treatment study in same eye. No additional control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in sub-foveal choroidal thickness (measured with swept source optical coherence tomography) in response to imposed retinal defocus with 2.00 Dioptre lens</outcome>
      <timepoint>Before and 22 hours after 1 drop of 0.5% atropine</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in para-foveal choroidal thickness (measured using swept source optical coherence tomography) in response to imposed retinal defocus with 2.00 Dioptre lens</outcome>
      <timepoint>before and 22 hours after 1 drop of 0.5% atropine</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>The inclusion criteria for this study were: Spherical Equivalent Refraction (SER) with spectacle prescription between -1.00 to -5.00 D, with little astigmatism (= 1.00 D) or anisometropia (= 1.00 D). </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>25</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Individuals with amblyopia, ocular pathology or other ocular anomalies (e.g. surgery, trauma) that might have influenced the measurements were excluded.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>24/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>12/03/2015</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>10</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>12/03/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Auckland</primarysponsorname>
    <primarysponsoraddress>85 Park Rd
Grafton
Auckland 1023</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>The University of Auckland</fundingname>
      <fundingaddress>85 Park Rd
Grafton
Auckland 1023</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress>NA</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Myopia of any degree increases the risk of developing sight-threatening conditions such as glaucoma, retinal detachment and myopic maculopathy with risk increasing dramatically with progression to high myopia.  Atropine eye drops are currently the most effective treatment for managing myopia progression, but the mode of action is unclear. The aim of this study was to investigate the effect of atropine eye drops on choroidal thinning induced by hyperopic retinal defocus, using automated measures of choroidal thickness obtained with swept-source optical coherence tomography (SS-OCT). A secondary aim was to record the short-term effect of atropine on the resting thickness of the choroid. </summary>
    <trialwebsite />
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Auckland Human Participants Ethics Committee</ethicname>
      <ethicaddress>The University of Auckland
Private Bag 92019
Auckland 1142</ethicaddress>
      <ethicapprovaldate>24/10/2013</ethicapprovaldate>
      <hrec>010617</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>John Phillips</name>
      <address>School of Optometry and Vision Science
The University of Auckland
85 Park Road
Grafton 
Auckland 1023</address>
      <phone>+64 9 923 6073</phone>
      <fax />
      <email>j.phillips@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>John Phillips</name>
      <address>School of Optometry and Vision Science
The University of Auckland
85 Park Road
Grafton 
Auckland 1023</address>
      <phone>+64 9 923 6073</phone>
      <fax />
      <email>j.phillips@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>John Phillips</name>
      <address>School of Optometry and Vision Science
The University of Auckland
85 Park Road
Grafton 
Auckland 1023</address>
      <phone>+64 9 923 6073</phone>
      <fax />
      <email>j.phillips@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>